renal cell carcinoma pipeline insight

DelveInsight’s, “Renal Cell Carcinoma- Pipeline Insight, 2025” report provides comprehensive insights about 70+ companies and 75+ pipeline drugs in Renal Cell Carcinoma pipeline landscape. It covers the pipeline drug profiles, including clinical and nonclinical stage products. It also covers the therapeutics assessment by product type, stage, route of administration, and molecule type. It further highlights the inactive pipeline products in this space.

 

Geography Covered

• Global coverage

 

Renal Cell Carcinoma: Understanding

Renal Cell Carcinoma: Overview

Renal Cell Carcinoma (RCC) is the most common type of kidney cancer, accounting for about 85–90% of all kidney malignancies. It originates in the renal tubules, which are part of the kidney’s filtration system. RCC is often asymptomatic in early stages and may be discovered incidentally during imaging for other conditions. In advanced stages, it can present with symptoms like blood in urine, flank pain, or a palpable mass. Treatment options include surgery, targeted therapy, and immunotherapy depending on the stage and spread of the disease.

Signs and symptoms of Renal Cell Carcinoma (RCC) can be subtle in early stages but may include blood in the urine (hematuria), persistent flank or back pain, and a palpable abdominal mass. Some patients experience unexplained weight loss, fatigue, or intermittent fever. In advanced cases, symptoms related to metastasis (e.g., bone pain or cough) may appear, Fever or night sweats – Not caused by infection, may indicate advanced disease.

 

Certain factors may increase your risk of developing Renal Cell Carcinoma. These include:

Smoking – Significantly increases the risk of RCC.

Obesity – Linked to hormonal and metabolic changes that may promote tumor growth.

Hypertension – Both the condition and some medications used to treat it are associated with RCC.

Family history – Especially of hereditary conditions like von Hippel-Lindau disease.

Occupational exposure – To chemicals like asbestos, cadmium, or petroleum products.

 

The proximal renal tubular epithelium is the kidney tissue from which RCC arises. The two forms are sporadic: nonhereditary and hereditary. The structural alterations of both forms occur on the short arm of chromosome 3 (3p). Families at high risk for developing renal cancer were studied, which led to the cloning of genes. The genes whose alteration resulted in RCC formation were tumor suppressors (VHL, TSC) or oncogenes (MET). People with RCC typically do not experience any symptoms during the early stages of the disease.

 

Renal Cell Carcinoma (RCC) is often diagnosed incidentally through imaging studies like ultrasound, CT scan, or MRI performed for unrelated reasons. Once a suspicious mass is identified, contrast-enhanced CT or MRI is typically used to assess tumor size, location, and potential spread. Urinalysis and blood tests help evaluate kidney function and detect abnormalities. In some cases, a biopsy may be performed to confirm the diagnosis, especially if the tumor is atypical or metastasis is suspected.

 

Treatment of Renal Cell Carcinoma (RCC) depends on the stage and spread of the disease. For localized RCC, surgical removal of the tumor through partial or radical nephrectomy is the primary treatment. In advanced or metastatic cases, targeted therapies (like tyrosine kinase inhibitors) and immunotherapies (such as immune checkpoint inhibitors) are commonly used. Active surveillance may be considered for small, slow-growing tumors in select patients. Radiation therapy is rarely used for the primary tumor but may help relieve symptoms from metastases. Treatment plans are often personalized based on tumor biology, patient health, and preferences.

 

"Renal Cell Carcinoma- Pipeline Insight, 2025" report by DelveInsight outlays comprehensive insights of present scenario and growth prospects across the indication. A detailed picture of the Renal Cell Carcinoma pipeline landscape is provided which includes the disease overview and Renal Cell Carcinoma treatment guidelines. The assessment part of the report embraces, in depth Renal Cell Carcinoma commercial assessment and clinical assessment of the pipeline products under development. In the report, detailed description of the drug is given which includes mechanism of action of the drug, clinical studies, NDA approvals (if any), and product development activities comprising the technology, Renal Cell Carcinoma collaborations, licensing, mergers and acquisition, funding, designations and other product related details.

 

Report Highlights

• The companies and academics are working to assess challenges and seek opportunities that could influence Renal Cell Carcinoma R&D. The therapies under development are focused on novel approaches to treat/improve Renal Cell Carcinoma.

 

Renal Cell Carcinoma Emerging Drugs Chapters

This segment of the Renal Cell Carcinoma report encloses its detailed analysis of various drugs in different stages of clinical development, including phase III, II, II/III I, preclinical and Discovery. It also helps to understand clinical trial details, expressive pharmacological action, agreements and collaborations, and the latest news and press releases.

 

Renal Cell Carcinoma Emerging Drugs

• Quavonlimab + pembrolizumab: Merck

Quavonlimab + Pembrolizumab (MK-1308A) is Merck's investigational fixed-dose combination of two immune checkpoint inhibitors: quavonlimab, an anti-CTLA-4 monoclonal antibody, and pembrolizumab (Keytruda), an anti-PD-1 monoclonal antibody. This dual immunotherapy approach is being evaluated in Phase 2 and 3 clinical trials for various cancers, including advanced non-small cell lung cancer (NSCLC), renal cell carcinoma (RCC), and microsatellite instability-high (MSI-H) or mismatch repair-deficient (dMMR) colorectal cancer. Early studies have demonstrated encouraging antitumor activity with a manageable safety profile, supporting further clinical development.

The drug is currently being investigated in the Phase III stage of development for the treatment of Renal Cell Carcinoma.

 

• HB0025: Huabo Biopharm Co., Ltd.

HB0025 is an investigational bispecific fusion protein developed by Huabo Biopharm Co., Ltd., designed to target both PD-L1 and VEGF pathways. It combines an anti-PD-L1 monoclonal antibody with the VEGFR1 domain, aiming to enhance anti-tumor immunity and inhibit angiogenesis. Preclinical studies suggest that HB0025 offers synergistic effects, potentially surpassing the efficacy of individual PD-L1 or VEGF inhibitors. Currently, HB0025 is undergoing Phase II clinical trials for various advanced solid tumors, including renal cell carcinoma, endometrial cancer, and non-small cell lung cancer. Currently, the drug is in the Phase II stage of its development for the treatment of Renal Cell Carcinoma.

 

• PRO1160: ProfoundBio US Co

PRO1160 is an investigational antibody-drug conjugate (ADC) developed by ProfoundBio, designed to target CD70—a protein overexpressed in various solid tumors and hematologic malignancies, including renal cell carcinoma (RCC), nasopharyngeal carcinoma (NPC), and non-Hodgkin lymphoma (NHL) . The ADC comprises a human monoclonal antibody specific for CD70, linked via a proprietary hydrophilic linker to exatecan, a potent topoisomerase I inhibitor. Preclinical studies have demonstrated PRO1160's robust antitumor activity and favorable pharmacokinetics. Currently, PRO1160 is undergoing a Phase I/II clinical trial to evaluate its safety, tolerability, pharmacokinetics, and antitumor activity in patients with advanced RCC, NPC, or NHL.

 

• KO-2806: Kura Oncology

KO-2806 is Kura Oncology’s next-generation farnesyl transferase inhibitor (FTI), engineered to enhance potency, pharmacokinetics, and physicochemical properties over earlier FTIs. Currently in Phase 1 clinical trials (FIT-001), KO-2806 is being evaluated both as a monotherapy and in combination with targeted therapies like cabozantinib for advanced solid tumors, including clear cell renal cell carcinoma (ccRCC), non-small cell lung cancer (NSCLC), and pancreatic ductal adenocarcinoma. Preclinical studies have shown that KO-2806 can augment the antitumor activity of tyrosine kinase inhibitors and potentially overcome resistance mechanisms in various cancers. The ongoing trial aims to assess its safety, tolerability, and preliminary efficacy across multiple tumor types. Currently the drug is in Phase I stage of its development for the treatment of Renal Cell Carcinoma.

Further product details are provided in the report……..

 

Renal Cell Carcinoma: Therapeutic Assessment

This segment of the report provides insights about the different Renal Cell Carcinoma drugs segregated based on following parameters that define the scope of the report, such as:

Major  Players in Renal Cell Carcinoma

There are approx. 70+ key companies which are developing the therapies for Renal Cell Carcinoma. The companies which have their Renal Cell Carcinoma drug candidates in the most advanced stage, i.e. Phase III include, Merck.

 

Phases

DelveInsight’s report covers around 75+ products under different phases of clinical development like

• Late stage products (Phase III)
• Mid-stage products (Phase II)
• Early-stage product (Phase I) along with the details of
• Pre-clinical and Discovery stage candidates
• Discontinued & Inactive candidates

 

Route of Administration

Renal Cell Carcinoma pipeline report provides the therapeutic assessment of the pipeline drugs by the Route of Administration. Products have been categorized under various ROAs such as

• Intravenous
• Subcutaneous
• Oral
• Intramuscular

 

Molecule Type

Products have been categorized under various Molecule types such as

• Monoclonal antibody
• Small molecule
• Peptide

 

Product Type

Drugs have been categorized under various product types like Mono, Combination and Mono/Combination.

 

Renal Cell Carcinoma: Pipeline Development Activities

The report provides insights into different therapeutic candidates in phase II, I, preclinical and discovery stage. It also analyses Renal Cell Carcinoma therapeutic drugs key players involved in developing key drugs.

 

Pipeline Development Activities

The report covers the detailed information of collaborations, acquisition and merger, licensing along with a thorough therapeutic assessment of emerging Renal Cell Carcinoma drugs.

 

Renal Cell Carcinoma Report Insights

• Renal Cell Carcinoma Pipeline Analysis
• Therapeutic Assessment
• Unmet Needs
• Impact of Drugs

 

Renal Cell Carcinoma Report Assessment

• Pipeline Product Profiles
• Therapeutic Assessment
• Pipeline Assessment
• Inactive drugs assessment
• Unmet Needs

 

Key Questions

Current Treatment Scenario and Emerging Therapies:

• How many companies are developing Renal Cell Carcinoma drugs?
• How many Renal Cell Carcinoma drugs are developed by each company?
• How many emerging drugs are in mid-stage, and late-stage of development for the treatment of Renal Cell Carcinoma?
• What are the key collaborations (Industry–Industry, Industry–Academia), Mergers and acquisitions, licensing activities related to the Renal Cell Carcinoma therapeutics?
• What are the recent trends, drug types and novel technologies developed to overcome the limitation of existing therapies?
• What are the clinical studies going on for Renal Cell Carcinoma and their status?
• What are the key designations that have been granted to the emerging drugs?